Brainomix has announced the upcoming launch of its new Brainomix 360 next-generation platform at the International Stroke Conference (ISC; 4–6 February 2026, New Orleans, USA). This new platform and feature upgrade provides a first-of-its-kind net water uptake (NWU) capability using routine non-contrast computed tomography (NCCT) scans, as well as an award-winning user experience, as per a press release from the company.
At ISC 2026, Brainomix is also set to present five abstracts—including an oral presentation—highlighting the value and impact of Brainomix 360 Stroke, building on its existing evidence base.
The next generation of Brainomix 360 Stroke sets “a new benchmark” for user experience and innovation, having recently been selected from more than 20,000 submissions spanning 60 countries to receive the Red Dot Design Award, according to Brainomix.
With enhanced digital imaging and communications in medicine (DICOM) viewing capabilities and artificial intelligence (AI)-driven, patient-specific insights, the platform supports streamlined workflows that enable fast, confident and informed decision-making.
The company’s industry-first, regulatory-cleared NWU capability is fully automated and features a percentage-based output that is said to “extend Brainomix’s leadership in simple imaging”, unlocking expert-level insights from routine NCCT scans with the ultimate goal of supporting improved treatment and transfer decisions.
“We are delighted to introduce this latest innovation in stroke AI imaging, building on our expertise in universally available CT imaging,” said George Harston (Oxford University Hospitals, Oxford, UK), chief medical and innovation officer at Brainomix. “The automated net water uptake output complements Brainomix’s unique ischaemic core volume and e-ASPECTS [Alberta stroke programme early CT score] features to provide clinicians across all hospital settings with deeper insights into stroke injury using a routine non-contrast CT scan. Emerging evidence is increasingly highlighting NWU as a vital imaging biomarker to inform treatment decisions and improve prognostication in the most severe strokes. In a world where stroke patients are missing out on effective treatments due to clinical uncertainty, we hope this latest advance can improve the confidence of physicians—even when treating the most severe strokes.”
The studies on Brainomix’s technology set to be presented at ISC 2026 include a cost-effectiveness analysis showing that widespread adoption of Brainomix 360 Stroke could significantly increase rates of thrombolysis and thrombectomy, delivering improved functional outcomes, better long-term health quality, and a net monetary benefit; validation of an imaging foundation model to automate follow-up infarct volume (FIV) segmentation; a prospective performance validation of Brainomix 360 Triage large vessel occlusion (LVO); the clinical impact of collateral circulation dynamics during interhospital transfer; and a novel approach to enhance the detection of stroke mimics.
